(Q37569035)

English

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

scientific article published on August 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). (English)

1 reference

Europe PubMed Central

21 August 2017

0 references

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

author name string

Aminah Jatoi

1

1 reference

Europe PubMed Central

21 August 2017

Kendrith Rowland

2

1 reference

Europe PubMed Central

21 August 2017

Jeff A Sloan

3

1 reference

Europe PubMed Central

21 August 2017

Howard M Gross

4

1 reference

Europe PubMed Central

21 August 2017

Paul A Fishkin

5

1 reference

Europe PubMed Central

21 August 2017

Stephen P Kahanic

6

1 reference

Europe PubMed Central

21 August 2017

Paul J Novotny

7

1 reference

Europe PubMed Central

21 August 2017

Paul L Schaefer

8

1 reference

Europe PubMed Central

21 August 2017

David B Johnson

9

1 reference

Europe PubMed Central

21 August 2017

Loren K Tschetter

10

1 reference

Europe PubMed Central

21 August 2017

Charles L Loprinzi

11

1 reference

Europe PubMed Central

21 August 2017

language of work or name

0 references

publication date

1 August 2008

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

113

1 reference

Europe PubMed Central

21 August 2017

4

1 reference

Europe PubMed Central

21 August 2017

847-853

1 reference

Europe PubMed Central

21 August 2017

Tetracyclines and pulmonary inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

23 August 2017

New agents, new rashes: an update on skin complications from cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

23 August 2017

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

23 August 2017

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

23 August 2017

A review of erlotinib and its clinical use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

23 August 2017

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

23 August 2017

Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

23 August 2017

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

23 August 2017

Systemic antibiotics for acne

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

25 June 2018

Treatment of acne vulgaris with tetracycline hydrochloride: a double-blind trial with 51 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

25 June 2018

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

1 September 2018

Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3918166

1 September 2018

Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18543329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23621

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement properties of skindex-16: A brief quality-of-life measure for patients with skin diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23621

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23621

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37569035&oldid=2134508981"